Human CD3E&CD3D Heterodimer Protein is produced by co-expression of CD3E and CD3D, has a calculated MW of 40.2 kDa (CD3E) and 37.3 kDa (CD3D). Subunit CD3E is fused with a human IgG1 Fc tag and a polyhistidine tag at the C-terminus and subunit CD3D is fused with a human IgG1 Fc tag and a flag tag at the C-terminus. As a result of glycosylation, the heterodimer protein migrates as 45-60 kDa under reducing (R) condition, and 100-116 kDa under non-reducing (NR) condition (SDS-PAGE).
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 . Normally Trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
After reconstitution, this product is stable after storage at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human CD3E&CD3D Heterodimer Protein on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human CD3E&CD3D Heterodimer Protein (Cat. No. CDD-H52Wa) is more than 85% and the molecular weight of this protein is around 80-90 kDa verified by SEC-MALS.
Immobilized Human CD3E&CD3D Heterodimer Protein (Cat. No. CDD-H52Wa) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD3 Antibody, Mouse IgG2a (Clone: OKT3), Ultra-low endotoxin (Cat. No. CDE-M120a) with a linear range of 0.2-3 ng/mL (QC tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.